Clinical Trial Update: Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc [Phase 1]

View source ↗

Summary

Phase 1 study of autologous CAR-T cells targeting B7-H3 (CAR.B7-H3Tc) for recurrent or refractory glioblastoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CAR.B7-H3Tc

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Glioblastoma Multiforme | Phase 1 | Status: RECRUITING